Skin
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes - Neoadjuvant Systemic Treatment With Nivolumab and Relatlimab in Surgically Resectable Melanoma"
FEATURING
Liz Burton
- 105 views
- July 22, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "My Personal Highlights in Melanoma"
FEATURING
Sapna Patel
- 621 views
- July 11, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuvant Treatments, 1L Metastatic & Anti-PD-1 Refractory Disease"
FEATURING
Zeynep Eroglu
- 296 views
- July 5, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and Refractory Melanoma"
FEATURING
Douglas Johnson
- 406 views
- June 7, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Insights in Melanoma"
FEATURING
Omid Hamid
- 362 views
- June 21, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"
FEATURING
Sapna Patel
- 52 views
- June 19, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We Been and Where Are We"
FEATURING
Pippa Corrie
- 208 views
- June 20, 2024
- 1
ecancer
ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi vs. Adjuvant Nivo in Stage III Melanoma"
FEATURING
Christian Blank
- 34 views
- June 20, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Adopting Cutting-Edge Cell Therapies in Melanoma"
FEATURING
Allison Betof Warner
- 174 views
- June 11, 2024
ecancer
ASCO® 2024 Insights: "PIVOTAL Study - Neoadjuvant Daromun vs. Immediate Surgery in Fully Resectable Melanoma"
FEATURING
Axel Hauschild
- 30 views
- June 20, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"
FEATURING
Judith Lijnsvelt
- 44 views
- June 14, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "PIVOTAL Study - Daromun vs. Immediate Surgery in Resectable Melanoma With Regional Metastases"
FEATURING
Axel Hauschild
- 57 views
- June 11, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcomes - Nivo + Rela vs. Nivo for Previously Untreated Metastatic/Unresectable Melanoma"
FEATURING
Hussein Tawbi
- 306 views
- June 12, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macroscopic, Resectable Stage 3 Melanoma"
FEATURING
Christian Blank
- 239 views
- June 14, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "SCOPE Trial - Efficacy & Safety of SCIB1 Vaccine With Nivo & Ipi in Advanced Unresectable Melanoma"
FEATURING
Heather Shaw
- 12 views
- June 13, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"
FEATURING
Harriet Kluger
- 111 views
- June 10, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Immunotherapy & Beyond - Advances in Systemic Therapy for Patients With Melanoma and Brain Metastases"
FEATURING
Hussein Tawbi
- 160 views
- June 12, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "PD-1-Refractory Advanced Melanoma - Getting to the Finish Line"
FEATURING
Meredith Mckean
- 124 views
- June 10, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"
FEATURING
Paolo A. Ascierto
- 32 views
- June 12, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers"
FEATURING
Anna Maria Di Giacomo
- 31 views
- June 12, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157 & Pembro in Resected Melanoma"
FEATURING
Jeffrey Weber
- 207 views
- June 12, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "RELATIVITY-048 Trial - Efficacy and Safety of Triplet Nivo + Rela + Ipi in Advanced Melanoma"
FEATURING
Paolo A. Ascierto
- 185 views
- June 12, 2024
- 3
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "RegoMel Trial - Regorafenib in Patients With Pretreated Advanced Melanoma"
FEATURING
Iris Dirven
- 27 views
- June 7, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "OBX-115, IL2-Sparing Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Unresectable/Metastatic Melanoma"
FEATURING
Rodabe Amaria
- 14 views
- June 11, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in Stage III BRAF-Mutated Melanoma"
FEATURING
Axel Hauschild
- 469 views
- June 11, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Individualized Neoantigen Therapy mRNA-4157 (V940) + Pembro in Resected Melanoma"
FEATURING
Meredith Mckean
- 13 views
- June 11, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Novel RNA-Nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy"
FEATURING
Bently Doonan
- 32 views
- June 6, 2024